Acceptable Toxicity And Good Hematological And Renal Responses After Autologous Hematopoietic Stem Cell Transplantation In Multiple Myeloma Patients With Renal Insufficiency At Transplant: A Prospective Sfgm-Tc Observational Study

Background: High dose melphalan (HDM) followed by autologous hematopoietic stem cell transplantation (ASCT) is widely used in multiple myeloma (MM) patients as upfront and salvage therapy. However, the safety and efficacy of ASCT in patients with renal insufficiency (RI) is controversial, which have led to an inconsistent arbitrary cut-off for creatinine clearance (CrCl) for performing ASCT. Here we analyzed prospectively the outcomes of MM patients with severe RI who underwent ASCT.